# Lantheus

Source: https://onco.cc/companies/lantheus/  
OnCo record `lantheus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026; in August 2026 it agreed to be bought by Curium, a deal not yet closed.

## Summary

Lantheus, based in Bedford, Massachusetts, and listed as LNTH, makes Pylarify, or piflufolastat F-18, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026. Its portfolio also includes Neuraceq for amyloid imaging, PNT2002, a 177Lu-PSMA-I&T therapy whose SPLASH phase 3 missed overall survival, and PNT2003, a generic 177Lu-DOTATATE, and OnCo also links it to iobenguane I-131 and samarium-153 lexidronam. It connects to prostate cancer, to PET tracer manufacturing and distribution and radionuclide generators, and to Evergreen Theragnostics, which it acquired on 1 April 2025, and it also bought Life Molecular Imaging, the maker of Neuraceq, on 21 July 2025. On 3 August 2026 Lantheus agreed to be acquired by Curium for 102.50 dollars a share in cash plus a contingent value right of up to 12 dollars; stockholders approved the merger on 14 October 2026, the US Federal Trade Commission issued a second request on 21 October, and the companies expect to close in the first half of 2027. Whether an imaging leader can become a therapy company after SPLASH is the open question. Piflufolastat F-18 has its own page.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Progenics Pharmaceuticals, Inc.; Progenics; Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals
- HQ: Bedford, MA
- Type: radiopharma
- Website: https://www.lantheus.com
- Ticker: LNTH

## Notes

- Freshened 29 October 2026 from Lantheus SEC filings: completion 8-Ks for Evergreen Theragnostics (1 April 2025) and Life Molecular Imaging (21 July 2025), the Curium merger agreement 8-K (3 August 2026), the special meeting result (14 October 2026) and the FTC second-request 8-K (21 October 2026). The Curium deal had not closed on 29 October 2026, so the stage is unchanged. No total deal value is stated in the 8-K, so none is given here.

## Sources

- Official website: https://www.lantheus.com
- Curium merger agreement (SEC 8-K, August 2026): https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/d167446d8k.htm
- FTC second request (SEC 8-K, October 2026): https://www.sec.gov/Archives/edgar/data/1521036/000119312526428324/d19181d8k.htm
- Life Molecular Imaging completion (SEC 8-K, July 2025): https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/d89717d8k.htm

## Connected records

- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- drugs: [131I-MIBG (iobenguane I-131) therapy](https://onco.cc/drugs/i131-mibg/), [177Lu-PSMA-I&T](https://onco.cc/drugs/lu177-psma-it/), [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/), [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/)
- companies: [Curium](https://onco.cc/companies/curium/), [Evergreen Theragnostics](https://onco.cc/companies/evergreen-theragnostics/)
- trials: [64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer](https://onco.cc/trials/nct06298916/), [Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)](https://onco.cc/trials/nct07357519/), [SPLASH](https://onco.cc/trials/splash/), [Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer](https://onco.cc/trials/nct02981368/), [Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer](https://onco.cc/trials/nct03739684/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)](https://onco.cc/technologies/cyclotron-isotope-production/), [PET tracer manufacturing and distribution](https://onco.cc/technologies/pet-tracer-manufacturing/), [Radionuclide generators and cold kits](https://onco.cc/technologies/radionuclide-generators-kits/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/)

---
JSON: https://onco.cc/api/v1/entities/lantheus.json